Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene LabBGLC +3.33%56 Days Inventory is 955.95 as of Jun. 2026, which is 1958% above its 10-year median of 46.46. GuruFocus rates BGLC with a GF Score™ of 56/100 and a GF Value™ of $1.25 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,549 Chemicals companies, BioNexus Gene Lab ranks worse than 69.08% on this metric.
The historical rank and industry rank for BioNexus Gene Lab's Days Inventory or its related term are showing as below:
BGLC'
s Days Inventory Range Over the Past 10 Years
Min: 22.35 Med: 46.46 Max: 112.39
Current: 112.39
During the past 8 years, BioNexus Gene Lab's highest Days Inventory was 112.39. The lowest was 22.35. And the median was 46.46.
BGLC's Days Inventory is ranked worse than 69.08% of 1549
companies
in the Chemicals industry
Industry Median: 80.34
vs BGLC: 112.39
BioNexus Gene Lab's Days Inventory
increased
from Jun. 2025 (57.75) to Jun. 2026 (955.95).
It might indicate that BioNexus Gene Lab's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
BioNexus Gene Lab's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.10.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioNexus Gene Lab's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 8.68.
BioNexus Gene Lab (NAS:BGLC) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
BioNexus Gene Lab's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioNexus Gene Lab's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
BioNexus Gene Lab Days Inventory Related Terms
BioNexus Gene Lab Days Inventory Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLC vs VYST, QGAI, CNEY: Days Inventory Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Days Inventory vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Days Inventory distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a Days Inventory of 955.95 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BioNexus Gene Lab and its competitors. This is 1958% above median its historical median of 46.46. Over the past decade, BioNexus Gene Lab's Days Inventory has ranged from 22.35 to 112.39. According to the industry distribution chart, BioNexus Gene Lab ranks #1070 out of 1549 companies in the Chemicals industry, placing it in the top 69.1%.
Is BioNexus Gene Lab's Days Inventory too high?
BioNexus Gene Lab's current Days Inventory of 955.95 is 1958% above median its 10-year median of 46.46. Over the past 10 years, this metric has ranged from a low of 22.35 to a high of 112.39. The Chemicals industry median Days Inventory is 80.34. BioNexus Gene Lab's value of 955.95 is 1089.9% above this industry median. Based on the distribution chart, BioNexus Gene Lab ranks #1070 out of 1549 companies in the Chemicals industry, which is below the industry midpoint. Overall, BioNexus Gene Lab has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Days Inventory compare to VYST and QGAI?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #1070 out of 1549 companies for Days Inventory. This places BioNexus Gene Lab in the lower half of its industry. The industry median Days Inventory is 80.34. BioNexus Gene Lab's value of 955.95 is 1089.9% above this benchmark. Historically, BioNexus Gene Lab's own Days Inventory has ranged from 22.35 to 112.39 over the past decade. While the company's 10-year median is 46.46 vs. the industry median of 80.34, BioNexus Gene Lab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Chemicals company?
The median Days Inventory among Chemicals companies is 80.34, based on 1,549 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNexus Gene Lab's current Days Inventory of 955.95 is 1089.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BioNexus Gene Lab and its competitors. For the Chemicals industry, the median Days Inventory is 80.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current Days Inventory is 955.95, which is 1958% above median its own 10-year median of 46.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $1.55 — trading 24% above its estimated fair value. The current Days Inventory is 955.95, which is 1958% above median its 10-year median of 46.46 and 1089.9% above the Chemicals industry median of 80.34. BioNexus Gene Lab's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Days Inventory is 955.95 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be overvalued.
The current stock price of $1.55 is trading 24% above its estimated GF Value™ of $1.25.
GuruFocus considers BioNexus Gene Lab to be Modestly Overvalued.
Key valuation signals for BGLC:
Days Inventory: 955.95 (1958% above median its 10-year median of 46.46)
GF Value™: $1.25 vs. price of $1.55 (24% above fair value)
Industry Position: 1089.9% above the Chemicals median (#1070 of 1549)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
56GF Score
Get the complete analysis for BGLC
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
